Dbv Technologies ADR (DBVT)

Jun 3, 2025, 4:30 PM EDT - 3 days ago

DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document

May 15, 2025, 4:30 PM EDT - 22 days ago

Combined General Meeting of June 11, 2025

May 5, 2025, 4:30 PM EDT - 4 weeks ago

DBV Technologies to Participate in the Citizens JMP Life Sciences Conference

Apr 30, 2025, 4:00 PM EDT - 5 weeks ago

DBV Technologies Reports First Quarter 2025 Financial Results

Apr 11, 2025, 4:30 PM EDT - 2 months ago

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

Mar 28, 2025, 11:09 AM EDT - 2 months ago

DBV Technologies ADRs Rise After Up to $306.9M in New Financing

Mar 27, 2025, 10:30 PM EDT - 2 months ago

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved

Mar 24, 2025, 2:30 AM EDT - 2 months ago

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results

Feb 25, 2025, 4:01 PM EST - 3 months ago

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress

Jan 13, 2025, 4:05 PM EST - 5 months ago

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Dec 12, 2024, 9:59 AM EST - 6 months ago

DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids

Dec 11, 2024, 4:05 PM EST - 6 months ago

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old

Nov 11, 2024, 4:30 PM EST - 7 months ago

DBV Technologies Announces Plan to Implement ADS Ratio Change

Nov 6, 2024, 4:30 PM EST - 7 months ago

DBV Technologies Reports Third Quarter 2024 Financial Results

Oct 22, 2024, 4:45 PM EDT - 8 months ago

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe

Oct 18, 2024, 4:30 PM EDT - 8 months ago

DBV Technologies to Participate in Upcoming ACAAI 2024 Congress

Sep 23, 2024, 4:30 PM EDT - 9 months ago

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

Sep 4, 2024, 4:30 PM EDT - 9 months ago

DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Jul 30, 2024, 10:03 PM EDT - 11 months ago

DBV Technologies S.A. (DBVT) Q2 2024 Earnings Call Transcript

Jul 30, 2024, 5:30 PM EDT - 11 months ago

DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report

Jul 30, 2024, 4:30 PM EDT - 11 months ago

DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results

Jul 29, 2024, 1:30 AM EDT - 11 months ago

DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024

Jun 5, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 30, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies to Participate in Upcoming EAACI 2024 Congress

May 16, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies Announces Results of its 2024 Combined General Meeting

May 9, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies to Participate in Upcoming Investor Conferences

May 7, 2024, 4:30 PM EDT - 1 year ago

DBV Technologies Reports First Quarter 2024 Financial Results and Business Update

Apr 25, 2024, 4:30 PM EDT - 1 year ago

Combined General Meeting of May 16, 2024

Mar 8, 2024, 9:33 AM EST - 1 year ago

DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

Mar 7, 2024, 9:58 PM EST - 1 year ago

DBV Technologies S.A. (DBVT) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 4:30 PM EST - 1 year ago

DBV Technologies Reports Full Year 2023 Financial Results and Business Update

Mar 4, 2024, 4:30 PM EST - 1 year ago

DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024

Feb 20, 2024, 4:30 PM EST - 1 year ago

DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

Dec 1, 2023, 10:47 AM EST - 1 year ago

Top 5 Health Care Stocks That Could Blast Off In December - DBV Technologies (NASDAQ:DBVT), Cigna Group (NYSE:CI)

CI MD PDCO

Nov 9, 2023, 4:30 PM EST - 1 year ago

DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers

Nov 2, 2023, 4:30 PM EDT - 1 year ago

DBV Technologies to Present New Data at ACAAI 2023

Oct 31, 2023, 9:57 PM EDT - 1 year ago

DBV Technologies S.A. (DBVT) Q3 2023 Earnings Call Transcript

Oct 31, 2023, 4:30 PM EDT - 1 year ago

DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results

Oct 27, 2023, 4:30 PM EDT - 1 year ago

DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update

Oct 16, 2023, 2:00 AM EDT - 1 year ago

DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer

Sep 5, 2023, 4:30 PM EDT - 1 year ago

DBV Technologies to Participate in Upcoming Investor Conference

Jul 31, 2023, 8:02 PM EDT - 2 years ago

DBV Technologies S.A. (DBVT) Q2 2023 Earnings Call Transcript

Jul 31, 2023, 4:25 PM EDT - 2 years ago

DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results

Jul 25, 2023, 4:30 PM EDT - 2 years ago

DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update

Jun 8, 2023, 4:30 PM EDT - 2 years ago

DBV Technologies to Participate in Upcoming EAACI Congress 2023

May 10, 2023, 5:30 PM EDT - 2 years ago

DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers

May 4, 2023, 4:30 PM EDT - 2 years ago

DBV Technologies Reports First Quarter 2023 Financial Results

Apr 19, 2023, 5:09 PM EDT - 2 years ago

DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA

Apr 12, 2023, 4:30 PM EDT - 2 years ago

DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting

Mar 24, 2023, 4:30 PM EDT - 2 years ago

Ordinary and Extraordinary General Meeting of April 12, 2023